SCHEMBL289859

SCHEMBL289859

CCOc1ccc(C(=O)c2coc3c(Cl)c(Cl)c(O)cc23)cc1OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
PTGS2 P35354 1/20 0.46
SIRT1 Q96EB6 1/20 0.41
NPC1 O15118 1/20 0.40
USP2 O75604 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TSHR P16473 1/20 0.40
LTC4S Q16873 1/20 0.39
MAPK1 P28482 2/20 0.39
POLB P06746 3/20 0.39
MAPT P10636 1/20 0.38
CREBBP Q92793 1/20 0.38
PDF Q9HBH1 1/20 0.38
ALDH1A1 P00352 2/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL290614 0.85 PDF (0.53) PTGS2SIRT1NPC1SMN1; SMN2TSHR
SCHEMBL289564 0.78 PTGS2 (0.54) LMNAPTGS2SIRT1NPC1USP2
SCHEMBL289170 0.78 PTGS2 (0.71) LMNAPTGS2SIRT1NPC1USP2
SCHEMBL289724 0.78 NPC1 (0.57) PTGS2SIRT1NPC1RAB9ASMN1; SMN2
SCHEMBL290348 0.77 PTGS2 (0.59) LMNAPTGS2SIRT1NPC1USP2
SCHEMBL290051 0.77 PDF (0.52) PTGS2MAPTPDF
SCHEMBL290351 0.76 KMT2A (0.54) LMNAPTGS2SIRT1NPC1USP2
SCHEMBL290273 0.76 PTGS2 (0.64) LMNAPTGS2SIRT1NPC1USP2
SCHEMBL290349 0.72 PTGS2 (0.49) LMNAPTGS2SIRT1NPC1USP2
SCHEMBL16994961 0.72 PTGS2 (0.46) LMNAPTGS2SIRT1NPC1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2959898-A1 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2015-12-30 EP disclosed
EP-2427057-B1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN KETTERING INST CANCER (US) 2015-08-12 EP disclosed
US-8614237-B2 Benzofuran-4,5-diones as selective peptide deformylase inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-12-24 US disclosed
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-03-22 US disclosed
EP-2427057-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2012-03-14 EP disclosed
WO-2010129049-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS PDF, EIF5B, EIF4E LMNA 3542/4885PTGS2 2098/4885SIRT1 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.